Physician profile
Sandeep Chandra
NPI 1093801029
$11,450.45
in general payments reported to CMS, 2019-2025
41 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $1,762 · 2021: $2,180 · 2022: $1,600 · 2023: $1,197 · 2024: $1,326 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,671.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,258.49 | 2019-2025 | |
| Amgen INC. | $1,149.53 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $945.68 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $675.15 | 2019-2025 | Wainua, Farxiga |
| Pfizer INC. | $612.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $540.33 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.36 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $519.59 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $476.76 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $380.41 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $365.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $344.00 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $237.99 | 2019-2024 | |
| Amarin Pharma, INC. | $233.02 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $188.16 | 2023-2025 | Edarbyclor, Edarbi, Horizant |
| Lilly USA, LLC | $186.21 | 2019-2024 | Mounjaro |
| Boston Scientific Corporation | $178.05 | 2019-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $166.05 | 2022-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $149.85 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $110.73 | 2019-2025 | Praluent, Evkeeza |
| Alnylam Pharmaceuticals INC. | $108.06 | 2021-2024 | Onpattro |
| Lundbeck LLC | $92.00 | 2019-2020 | |
| Edwards Lifesciences Corporation | $79.02 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Gilead Sciences, INC. | $33.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $28.09 | 2019 | |
| Inspire Medical Systems, INC. | $26.26 | 2025 | Inspire |
| Abbott Laboratories | $24.45 | 2022 | |
| Bardy Diagnostics, INC. | $24.00 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $19.18 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.14 | 2022 | |
| Irhythm Technologies, INC. | $16.29 | 2024 | Zio Xt Patch |
| Cleerly, INC. | $15.55 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Scpharmaceuticals INC. | $15.39 | 2023 | |
| Kestra Medical Technology Services, INC. | $14.03 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.58 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.97 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.